• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Atossa Therapeutics, Inc. - Common Stock (NQ:ATOS)

    2.635 +0.075 (+2.93%)
    Delayed Quote Updated: 1:51 PM EDT, Oct 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Atossa Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split ↗
    Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2,... 
    Via Stocktwits
    Get insights into the top gainers and losers of Friday's after-hours session. ↗
    Via Chartmill
    News headline image
    Why Did ATOS Stock Jump 10% In Pre-Market Today? ↗
    The U.S. Food and Drug Administration granted Orphan Drug Designation to its (Z)-Endoxifen therapy for DMD. 
    Via Stocktwits
    News headline image
    Why Are Shares Of Atossa Therapeutics Up Today? ↗
    Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know. 
    Via Benzinga
    Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track ↗
    Via Stocktwits
    News headline image
    MicroMarvel - Atossa Therapeutics ↗
    Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals 
    Via Talk Markets
    Atossa Therapeutics backing Endoxifen in the fight against breast cancer
    --News Direct-- 
    Via News Direct
    News headline image
    Get insights into the top gainers and losers of Thursday's pre-market session. ↗
    As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
    Via Chartmill
    News headline image
    This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For March 25, 2025 ↗
     
    Via Benzinga
    News headline image
    Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday ↗
     
    Via Benzinga
    News headline image
    ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024 ↗
    ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    3 Dirt-Cheap Drug Developers With Blockbuster Potential ↗
    These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
    Via InvestorPlace
    News headline image
    3 Penny Stock Moonshots with 300%+ Upside Potential by 2025 ↗
    If you understand the risks of penny stocks with upside, you may want to investigate these three stocks today. 
    Via InvestorPlace
    News headline image
    Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar ↗
    These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials. 
    Via InvestorPlace
    News headline image
    3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off ↗
    With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. 
    Via InvestorPlace
    News headline image
    Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 ↗
    With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. 
    Via InvestorPlace
    News headline image
    ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024 ↗
    ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    News headline image
    Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar ↗
    Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider. 
    Via InvestorPlace
    News headline image
    ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023 ↗
    ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    News headline image
    Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market ↗
    In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for. 
    Via InvestorPlace
    News headline image
    This Drug Developer Is Dedicated To "Transforming The Breast Cancer Paradigm" ↗
    Dr. Steven Quay MD, PhD, President & CEO of Atossa Therapeutics Inc. (NASDAQ: ATOS) was recently interviewed by Benzinga. 
    Via Benzinga
    News headline image
    Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment ↗
    One in eight women will be diagnosed with breast cancer during 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst ↗
    Cantor Fitzgerald has initiated coverage of Atossa Therapeutics Inc (NASDAQ: ATOS) with an Overweight rating and  
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023 ↗
     
    Via Benzinga
    News headline image
    Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer? ↗
    Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the... 
    Via Benzinga
    News headline image
    50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis ↗
    One in eight women will be diagnosed with breast cancer during 
    Via Benzinga
    News headline image
    3 Penny Stocks to Make Your ‘Get Rich’ Dreams Come True ↗
    When it comes to potentially profitable penny stocks, some can create unimaginable fortunes for patient investors. Others, not so much. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.